Abstract:
Introduction:Hepatocholangiocarcinoma (HCC-ICC) is a rare tumor presenting the histologic characteristics of both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). As there is no consensus on it management, the therapeutic strategy rests on the specific treatments for HCC or ICC. Programmed cell death 1 (PD-1) inhibitors showed encouraging results in the second line treatment of HCC after sorafenib but it efficacy in HCC-ICC has never been reported. Methods and results:We present the case of a 72-year-old male patient treated for metastatic HCC-ICC due to a viral hepatitis C cirrhosis in progression after two lines of treatment. Tumor was characterized by a PDL-1 status of 85%. Patient received pembrolizumab at doses of 200 mg every 21 days by intravenous infusion. After one injection he was presented an immediate clinical benefit, a partial response was observed after two months of treatment and a complete response two months later. This response was maintained over time along with toxicity-free tumor control after 18 months treatment. Conclusion:To our knowledge, we reported for the first time the efficacy of a PD1 inhibitor treatment in a patient presenting metastatic HCC-ICC due to viral cirrhosis and overexpressing PDL-1 after failure of two lines of treatment.
journal_name
Therap Adv Gastroenteroljournal_title
Therapeutic advances in gastroenterologyauthors
Saint A,Benchetrit M,Novellas S,Ouzan D,Falk AT,Leysalle A,Barriere Jdoi
10.1177/1756284820935189subject
Has Abstractpub_date
2020-06-20 00:00:00pages
1756284820935189eissn
1756-283Xissn
1756-2848pii
10.1177_1756284820935189journal_volume
13pub_type
abstract::Hereditary pancreatitis shares a majority of clinical and morphologic features with chronic alcoholic pancreatitis, but may present at an earlier age. The term hereditary pancreatitis has primarily been associated with mutations in the serine protease 1 gene (PRSS1) which encodes for cationic trypsinogen. PRSS1 mutati...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X12467565
更新日期:2013-03-01 00:00:00
abstract:BACKGROUND:Diarrhea-predominant irritable bowel syndrome (IBS-D) impairs patient quality of life (QOL). Rifaximin is an oral, nonsystemic antibiotic indicated for IBS-D. The objective of this secondary analysis was to evaluate rifaximin retreatment on IBS-related QOL in patients with IBS-D. METHODS:Patients received o...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X17726087
更新日期:2017-09-01 00:00:00
abstract:Background:Variability in glucagon-like peptide (GLP)-1 and GLP-2 plasma concentrations has been suggested in Celiac disease (CD), with inconclusive results. We assessed the association between serum levels of GLP-1 and GLP-2 and their duodenal receptor expression in children with and without CD. Methods:This was a tw...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284819842756
更新日期:2019-04-17 00:00:00
abstract:Background:Recently the American Society for Gastrointestinal Endoscopy addressed the 'resect and discard' strategy, determining that accurate in vivo differentiation of colorectal polyps (CP) is necessary. Previous studies have suggested a promising application of artificial intelligence (AI), using deep learning in o...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284820910659
更新日期:2020-03-20 00:00:00
abstract:BACKGROUND:Endoscopic therapy for early neoplasia in Barrett's esophagus (BE) is evolving. Endoscopic resection has an increasing role. We wanted to evaluate the safety and efficacy of multi-band ligation/resection [ER-L] without pre-injection in BE with high-grade dysplasia [HGD] and intramucosal carcinoma [IMCA]. ME...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X09346794
更新日期:2009-11-01 00:00:00
abstract::The wireless motility capsule (WMC) is an ambulatory noninvasive and nonradioactive diagnostic sensor that continuously samples intraluminal pH, temperature, and pressure as it moves through the gastrointestinal (GI) tract. This review summarizes the data obtained in clinical trials with the WMC and discusses its role...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X12437874
更新日期:2012-07-01 00:00:00
abstract::Helicobacter pylori (H. pylori) are gram-negative bacteria that selectively colonizes the gastric mucosa. The prevalence of H. pylori infection varies from 20 to 50% in industrialized countries to over 80% in developing countries. The infection may persist lifelong without specific treatment. Prolonged infection and i...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X08094880
更新日期:2008-09-01 00:00:00
abstract:BACKGROUND:Mast cells (MCs) can stimulate angiogenesis, releasing several proangiogenic cytokines stored in their cytoplasm. In particular, MCs can release tryptase, a potent in vivo and in vitro proangiogenic factor via protease-activated receptor-2 (PAR-2) activation and mitogen-activated protein kinase (MAPK) phosph...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X16673981
更新日期:2017-04-01 00:00:00
abstract:BACKGROUND:Some chronic hepatitis C virus (HCV), genotype 1 infected patients treated with direct antiviral agents (DAAs) remain viremic at end of treatment (EOT+), yet go on to achieve sustained virological response 12 weeks after completion of therapy (SVR12). The incidence of EOT+/SVR in patients with genotype 1 and...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X16672392
更新日期:2017-01-01 00:00:00
abstract::In 2010, four independent groups almost simultaneously reported the association of the novel interleukin-1 (IL-1) family member, IL-33, with inflammatory bowel disease (IBD). The findings were remarkably consistent and demonstrated that IL-33 is markedly upregulated in, and specific to, ulcerative colitis (UC). In add...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X11410770
更新日期:2011-09-01 00:00:00
abstract::Clostridium difficile was first described as a cause of diarrhea in 1978 and in the last three decades has reached an epidemic state with increasing incidence and severity in both healthcare and community settings. There also has been a rise in severe outcomes from C. difficile infection (CDI). There have been tremend...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756283X13508519
更新日期:2014-03-01 00:00:00
abstract:BACKGROUND:Self-expandable metal stent (SEMS) placement is a minimally invasive treatment for palliation of malignant colorectal strictures and as a bridge to surgery. However, the use of SEMS for benign colorectal diseases is controversial. The purpose of this retrospective study is to evaluate the efficacy and safety...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X15610052
更新日期:2016-03-01 00:00:00
abstract::The intestinal microbiota consists of a dynamic organization of bacteria, viruses, archaea, and fungal species essential for maintaining gut homeostasis and protecting the host against pathogenic invasion. When dysregulated, the intestinal microbiota can contribute to colorectal cancer development. Though the microbio...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756283X17694832
更新日期:2017-05-01 00:00:00
abstract:Background:The environment surrounding Helicobacter pylori eradication treatment is dramatically changing. Recently, vonoprazan, a first-in-class potassium-competitive acid blocker (P-CAB), was introduced onto the market in 2015. The aging of Japan's demographic structure is becoming pronounced. In this study, we exami...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284819858511
更新日期:2019-07-04 00:00:00
abstract::Chronic hepatitis C (CHC) affects over 185 million individuals worldwide, approximately 3% of the world's population. CHC can lead to quality of life impairment, cirrhosis, hepatocellular carcinoma (HCC), liver failure and liver-related death. While CHC has been associated with increases in HCC, liver-related mortalit...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756283X15587481
更新日期:2015-09-01 00:00:00
abstract:Background:Recurrent Clostridium difficile infection (rCDI) is becoming increasingly common. Faecal microbiota transplantation (FMT) is effective for rCDI, but the costs of an FMT and hospital cost savings related to FMT are unknown. The aim of this study was to calculate the cost of an FMT and the total hospital costs...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284819843002
更新日期:2019-04-10 00:00:00
abstract::Nonalcoholic fatty liver disease (NAFLD) is becoming the most common cause of chronic liver disease in the developing world, found in 17-30% of the population in Western countries and 2-4% worldwide. Defined as the accumulation of fatty acid content greater than 5% of liver weight, NAFLD is a spectrum of disease rangi...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X11430859
更新日期:2012-05-01 00:00:00
abstract:Background:The clinical outcome of patients with obscure gastrointestinal bleeding (OGIB) during antithrombotic drug therapy has not been fully investigated. Methods:Patients who underwent video capsule endoscopy (VCE) for the investigation of OGIB at Okayama University Hospital from January 2009 to March 2016 were en...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X17746930
更新日期:2018-01-14 00:00:00
abstract::In recent years, mucosal healing has emerged as a key therapeutic goal in the clinical management of patients with Crohn's disease, as it has been associated with improved long-term clinical outcomes. With the vast improvements in endoscopic imaging techniques and the increase in available treatment options, which rep...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756284819856865
更新日期:2019-06-14 00:00:00
abstract::The treatment of hepatocellular carcinoma (HCC) remains a challenge, with 1- and 3-year survival rates of 20% and 5%, respectively, and a median survival of 8 months. However, a better understanding of the pathogenesis of HCC, and advances in targeted molecular therapies provide physicians treating this disease with n...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X09346669
更新日期:2010-01-01 00:00:00
abstract:Background:Pharmacotherapy, including prokinetics and proton pump inhibitors for functional dyspepsia (FD) have limited effectiveness, and their safety has been recently questioned. Chinese herbal medicine (CHM) could be considered as an alternative. A systematic review (SR) of SRs was performed to evaluate the potenti...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756284818785573
更新日期:2018-07-16 00:00:00
abstract::Crohn's disease (CD) is a chronic relapsing and remitting disorder of the gastrointestinal tract with no known cure. The inflammation that drives the disease can lead to debilitating symptoms and a number of complications that may lead to surgery. The introduction of biologic therapy a decade ago has offered a new opt...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X09357579
更新日期:2010-05-01 00:00:00
abstract:Background and Aims:Efficacy of adalimumab in Crohn's disease (CD) has not been shown in China. The aim of this study was to evaluate the efficacy and safety of adalimumab in Chinese patients with CD. Methods:This 26-week, multicenter, phase III study evaluated patients with moderately to severely active CD and elevat...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284820938960
更新日期:2020-07-16 00:00:00
abstract:BACKGROUND:Dual red imaging (DRI), a novel image-enhanced endoscopic technique, is expected to improve visibility of thin vessels, but no reports of the clinical use of DRI in colorectal endoscopic submucosal dissection (ESD) have been published. We aimed to compare the visibility of vessels, demarcation line between t...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X16645501
更新日期:2016-09-01 00:00:00
abstract::Malignant tumor cells are equipped with mechanisms that can help them escape the surveillance by host immune system. Immune checkpoint molecules can transduce coinhibitory signals to immunocompetent cells and exert immunosuppressive roles in antitumor immunity. Programmed death-1 (PD-1) and programmed death ligand-1 (...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756283X16658251
更新日期:2016-11-01 00:00:00
abstract:Background:Nonalcoholic fatty liver disease (NAFLD) is correlated with low-grade inflammation and dietary habits. Until today, there have been limited epidemiologic data assessing the role of diet's inflammatory potential on NAFLD. The aim was to evaluate the relationship between an anti-inflammatory diet, as reflected...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284819858039
更新日期:2019-06-23 00:00:00
abstract:BACKGROUND:Few reports have described endoscopic ultrasound (EUS)-guided fine needle aspiration (FNA) for biliary lesions. In addition, adverse events were not completely examined in previous reports, due to the inclusion of cases in which biliary stents had already been placed. The present study aimed to investigate t...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X15625584
更新日期:2016-05-01 00:00:00
abstract::Sex-based differences in inflammatory bowel disease (IBD) pathogenesis, disease course, and response to therapy have been increasingly recognized, however, not fully understood. Experimental and translational models have been leveraged to investigate hypothesized mechanisms for these observed differences, including th...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756284820915043
更新日期:2020-04-28 00:00:00
abstract:Background:One in four patients with primary Clostridioides difficile infection (CDI) develops recurrent CDI (rCDI). With every recurrence, the chance of a subsequent CDI episode increases. Early identification of patients at risk for rCDI might help doctors to guide treatment. The aim of this study was to externally v...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284820977385
更新日期:2021-01-09 00:00:00
abstract::Several clinical trials and experimental studies strongly suggest a place for Saccharomyces boulardii as a biotherapeutic agent for the prevention and treatment of several gastrointestinal diseases. S. boulardii mediates responses resembling the protective effects of the normal healthy gut flora. The multiple mechanis...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X11428502
更新日期:2012-03-01 00:00:00